Alluvi Tirzepatide and Retatrutide: Understanding the Difference

Alluvi tirzepatide and Retatrutide are often mentioned in the same searches, yet they do not have the same regulatory position. This guide explains the difference between authorised tirzepatide medicines, a tirzepatide research compound and investigational Retatrutide.

What is Tirzepatide?

Tirzepatide acts on GIP and GLP-1 receptors. Certain tirzepatide medicines are authorised in the UK for specific indications. They are prescription-only and should be supplied following clinical assessment through an appropriately registered provider and pharmacy.

What is Retatrutide?

Retatrutide is being studied as a triple receptor agonist involving GIP, GLP-1 and glucagon pathways. It remains investigational and is not an approved UK weight-loss medicine.

Why product status matters

A research-labelled compound is not interchangeable with an authorised medicine. Similar packaging, pen formats or marketing language cannot replace regulatory approval, clinical assessment or registered pharmacy supply.

Questions to ask when reviewing a listing

• Is this an authorised medicine or a research compound?
• Does the listing clearly state the intended purpose?
• Is a prescription and clinical assessment required?
• Can the batch reference be matched to its documentation?
• Are the supplier and laboratory details clear?

Alluvi product navigation

The term Alluvi tirzepatide should be checked against the exact product page. Review the stated category, specifications and available documentation. The Alluvi Healthcare UK homepage explains how the wider range is organised.

Related research information

For Retatrutide, read our UK research-status guide. For documentation checks, see how to read a Certificate of Analysis.

This educational article does not provide medical advice, prescribing guidance or instructions for use.